BETHLEHEM, Pa., Aug. 9, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has closed enrollment for its multi-site clinical study of the Company’s OraQuick® Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter (OTC) market.
